Michal Droppa and Tobias Geisler* Pages 484 - 489 ( 6 )
Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing Percutaneous Coronary Intervention (PCI). However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition. It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews the available evidence and application on cangrelor use in clinical practice.
Cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous coronary intervention.
Department of Cardiology and Cardiovascular Medicine, University Hospital of Tubingen, Tubingen, Department of Cardiology and Cardiovascular Medicine, University Hospital of Tubingen, Tubingen